Patents Assigned to EIT Pharma, Inc.
  • Treatment of hepatitis delta virus infection with interferon lambda
    Patent number: 12508297
    Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: December 30, 2025
    Assignee: EIT Pharma, Inc.
    Inventor: Eduardo Bruno Martins
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20250387377
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: January 17, 2025
    Publication date: December 25, 2025
    Applicant: EIT Pharma, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Treatment of hepatitis delta virus infection
    Patent number: 12290509
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: September 15, 2023
    Date of Patent: May 6, 2025
    Assignee: EIT Pharma, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn